Innovation Pharmaceuticals Inc (IPIX)

[58nout]

Karin this is correct but with the caveat that dapto revenue which is currently over 1B a year is more than double that of vanco. This brings to light the fact that with the coming generic availability of dapto which will not go away just as vanco never went away, Cellceutix will need the strength of a major partner who has the muscle to sell the Brilicidan story of superiority in cost effectiveness. I still have my money on Novartis.

GO CTIX